Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans

Anu Haveri[1]*, Nina Ekström[1]*, Anna Solastie[1], Camilla Virta[1], Pamela Österlund[1], Elina Isosaari[2],

Hanna Nohynek[1], Arto A Palmu[2], and Merit Melin[1]

* equal contribution

[1] Department of Health Security, Finnish Institute for Health and Welfare, Helsinki, Finland

[2] Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki, Finland

Corresponding authors: Anu Haveri and Nina Ekström, Finnish Institute for Health and Welfare, POB

30, 00271 Helsinki, Finland. anu.haveri@thl.fi; nina.ekstrom@thl.fi

Co-authors: anna.solastie@thl.fi; camilla.virta@thl.fi; pamela.osterlund@thl.fi; elina.isosaari@thl.fi;

hanna.nohynek@thl.fi; arto.palmu@thl.fi; merit.melin@thl.fi

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/eji.202149535.

Abbreviations: BAU: Binding antibody unit concentration; COVID-19: Coronavirus Disease 2019; FMIA: Fluorescent multiplex immunoassay; GMC: Geometric mean concentration; GMT: Geometric mean titer; Ig: Immunoglobulin; MNT: Microneutralization test; NAb: Neutralizing antibody; N: Nucleoprotein; PCR: Polymerase chain reaction; RBD: Receptor-binding domain; SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2; S: Spike protein; SFL: Spike full length; VOC: Variants of concern

Abstract

Most subjects develop antibodies to SARS-CoV-2 following infection. In order to estimate the duration of immunity induced by SARS-CoV-2 it is important to understand for how long antibodies persist after infection in humans. Here, we assessed the persistence of serum antibodies following wild-type SARS-CoV-2 infection at 8 and 13 months after diagnosis in 367 individuals. The SARS-CoV-2 spike immunoglobulin G (S-IgG) and nucleoprotein IgG (N-IgG) concentrations and the proportion of subjects with neutralizing antibodies (NAb) were assessed. Moreover, the NAb titers among a smaller subset of participants (n=78) against a wild-type virus (B) and variants of concern (VOCs): Alpha (B.1.1.7), Beta (B.1.351) and Delta (B.1.617.2) were determined. We found that NAb against the wild-type virus persisted in 89% and S-IgG in 97% of subjects for at least 13 months after infection. Only 36% had N-IgG by 13 months. The mean S-IgG concentrations declined from 8 to 13 months by less than one third; N-IgG concentrations declined by two thirds. Subjects with severe infection had markedly higher IgG and NAb levels and are expected to remain seropositive for longer. Significantly lower NAb titers against the variants compared to the wild-type virus, especially after a mild disease, suggests reduced protection against VOCs.

Introduction

Infection with Severe acute respiratory coronavirus 2 (SARS-CoV-2) induces antibodies in most subjects to viral nucleoprotein (N) and spike (S) glycoprotein (1). Neutralizing antibodies (NAb) against SARS-CoV-2 target the receptor-binding domain (RBD) of the S protein and sterically interfere with the binding of the viral S protein and the host's angiotensin-converting enzyme 2 (2, 3). NAb levels are highly predictive of protection against infection and clinical disease (4) and detectable NAb have been reported to persist in most subjects at least 6 to 12 months after infection (5-13). Previous findings suggest that neutralizing activity against the SARS-CoV-2 is mediated particularly by IgG1 and IgA antibodies (14, 15). However, as the concentration of anti-SARS-CoV-2 IgA antibodies has been shown to decline rapidly following infection (16-18), long-term neutralization is thus driven by IgG antibodies to the spike protein (16).

SARS-CoV-2 is constantly mutating yet most changes have little or no impact on its virulence (19). However, some changes are causing concerns regarding disease severity, viral transmissibility and potential escape from natural and vaccine-induced immunity (20). The World Health Organization (WHO) in collaboration with an international network of experts has characterized the variants of concern (VOC) (https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/). Reduced NAb levels as compared to the wild-type virus have been shown against VOCs, especially against the Beta variant, both after vaccination (13, 21-23) and 9 (13) and 12 months (12) after infection. A similar reduction in NAb titers has also been reported against the Delta variant from convalescent sera collected three to 12 months post symptoms or after vaccination (24, 25).

Previous infection with SARS-CoV-2 has shown to induce effective immunity and protection against reinfections in most individuals (26, 27). In animal studies, a protective antibody titer against SARS-CoV-2 infection has been suggested to be low (28, 29). Higher immunoglobulin G (IgG) antibody levels against SARS-CoV-2 among health care workers within three months after vaccination were found to be associated with lower infectivity (30). However, a protective threshold for humans is still

3

under debate and subject to the standardization of serological methods. The accumulating research data on the persistence of antibodies after natural infection, and NAbs in particular, will provide important insight into estimating for how long antibodies induced by Coronavirus disease 2019 (COVID-19) vaccination can be expected to persist and provide protection against emerging SARS-CoV-2 variants. In this study, we investigated the antibody persistence up to 14 months after natural SARS-CoV-2 infection and assessed the potential cross-protection by comparing the NAb levels of wild-type virus (B lineage) to three VOC strains Alpha (B.1.1.7), Beta (B.1.351) and Delta (B.1.617.2).

Results

Persistence and kinetics of SARS-CoV-2 antibodies

We first assessed the persistence of NAb and serum IgG antibodies specific to SARS-CoV-2 Spike full length (SFL)-IgG, RBD-IgG and N-IgG at 8 months following SARS-CoV-2 infection. We found that 89% (1148/1292) of the subjects had NAb against the wild-type virus, 96% (1240/1292) had antibodies to SFL and RBD (S-IgG) and 66% (846/1292) had N-IgG. We further assessed the persistence of NAb and IgG antibodies a year after SARS-CoV-2 infection by randomly selecting 367/652 subjects who had not received a SARS-CoV-2 vaccination of the 995 subjects who participated at both time points (Figure 1). Participant demographics and clinical characteristics for the selected cohort were similar to the overall cohort (Table 1). NAb, S-IgG and N-IgG antibodies were detected in 91%, 98% and 67% of subjects in the selected cohort at 8 months after infection, respectively (Table 2). One year after infection the proportion of positive samples was still high for NAb and S-IgG (89% (326/367) and 97% (356/367)), respectively, but had decreased to 36% (132/367) for N-IgG. The mean IgG concentrations decreased significantly (p<0.001) for SFL-IgG, RBD-IgG and N-IgG from 8 months (3.2, 2.3, 1.2 binding antibody unit concentrations (BAU)/ml) to 13 months (2.3, 1.7, 0.44 BAU/ml, respectively) after infection. The decrease in mean IgG concentration was more notable (-63%) for N-IgG compared to SFL-IgG (-28%) or RBD-IgG (-26%) (Figure 2).

Effect of disease severity, age and gender on SARS-CoV-2 antibodies

We observed higher mean N-IgG, SFL-IgG and IgG-RBD concentrations in subjects who had recovered from severe disease than in those with mild disease 8 months after infection (p<0.001; Figure 3). The difference was 2.0 to 7.4-fold, depending on the age group, and persisted for at least 13 months after infection (Figure 3, Table 3). The proportion of seropositive subjects remained high for S-IgG and NAb (100%) and relatively high for N-IgG (67%) a year after severe infection, compared to 97%, 87% and 32%, respectively, of those with a milder infection. A higher proportion (33%) of subjects in the elderly age group (≥60 years of age) had been hospitalized compared to the younger age groups (13% of 40 to 59 years and 6% of those 17 to 39 years of age). Elderly subjects (≥60 years of age) with mild infection had similar levels of S-IgG antibodies (Table 3) and an equally high proportion of them had NAb compared to younger subjects with mild infection. N-IgG concentrations were, however, higher among ≥60-year old subjects than in subjects <60 years of age with mild disease at 8 and 13 months after infection (p<0.01). We could not demonstrate any difference in N-, SFL- or RBD-IgG concentrations between males and females at 8 or 13 months after infection.

Comparison of NAb titers between a wild-type virus and three VOCs

A smaller age- and gender-matched subset of participants (n=78) of 13-month samples was randomly selected for NAb titration due to the laborious live-virus microneutralization test (MNT). The samples were re-analyzed against a wild-type virus isolated in Finland during 2020 and three VOCs (Alpha, Beta and Delta) isolated in Finland during 2021. The samples to be included in the NAb titration were selected based on a seropositive result (NAb titer ≥6) in the screening test.

Within the whole cohort (n=78), NAb titers were significantly lower for all VOCs (p<0.0001, Kruskal-Wallis test) compared to wild-type virus. This decrease in geometric mean titers (GMT) was more notable for the Beta (-77%) and Delta (-69%) variants than for the Alpha variant (-42%) (Table 4).

NAb titers for all VOCs correlated well with wild-type virus titers, yet a more pronounced correlation was seen for the Alpha and Delta variants and lower for the Beta variant (Supplementary Figure 1).

For both wild-type virus and the Alpha variant, the proportion of seropositive individuals with severe disease remained high 13 months after infection (Figure 4, Supplementary Table 1). Lower titers against the Alpha variant compared to the wild-type virus were seen in mild disease groups with an increasing proportion of low positive (borderline) or negative subjects. The greatest decrease of NAb titers was seen between the wild-type virus and the Beta variant with markedly lower GMTs and seropositivity with several borderline titers also in groups of severe disease. NAb titers and seropositivity for the Delta variant was also markedly lower compared to wild-type virus. The Delta GMT values placed between the GMTs of the Alpha and Beta variants, yet the seropositivity of severe disease groups was relatively well preserved (≥80%) compared to that of the Beta variant (65%).

For all viruses, the subjects who recovered from severe disease had overall 2.1 to 3.0-fold higher NAb titers compared to those with mild disease (p<0.01). The same finding was seen with all IgG concentrations. The difference in IgG concentrations between severe and mild disease was prominent in both sexes in the large study cohort (n=367). However, in the small cohort (n=78) only males with mild disease had markedly lower NAb titers and S-IgG concentrations compared to those recovered from severe disease (p<0.05, Supplementary Table 2). The difference was not statistically significant for females although the trend was similar.

NAb titers against wild-type virus were higher in the elderly group (≥60 years) compared to <60 years old (p=0.045) whereas NAb titers for VOCs did not differ significantly between age groups (Supplementary Table 3). We detected a strong and statistically significant correlation (p<0.0001) between NAb titers and S-IgG antibody concentrations indicating an overall parallel trend between severe and mild disease antibody levels (Figure 5).

Discussion

Studies of individuals who have recovered from SARS-CoV-2 infection are crucial in determining for how long antibodies persist after infection and whether these antibodies protect against re-infection. We showed that S-IgG antibodies and, most importantly, NAbs persist in most subjects for at least a year following SARS-CoV-2 infection. The concentration of N-IgG, on the contrary, declined among a large proportion of subjects. In accordance with previous observations (6, 8, 31), subjects with severe infection had higher N-IgG, S-IgG concentrations and NAb titers than subjects with mild infection and are expected to remain seropositive for a longer time.

Previous studies show that most patients recovering from COVID-19 have detectable antibody responses peaking at approximately one month after infection (7, 8, 32). Antibody levels to N and S protein antigens decline during the first few months with differences in isotype and antigen specificity of the antibody (7). The decay rate has been shown to slow down thereafter (12). The relatively rapid early decline in S-IgG antibodies followed by slower decay indicates a transition of serum antibodies from being produced by short-lived plasmablasts to a more persistent population of long-lived plasma cells generated later in the immune response (33). Consistently, NAbs and T cell immunity have been reported to persist at least 6 to 12 months after infection (6-8, 11-13, 34). Our data is consistent with previous data suggesting that, even though NAb titers decline with time, NAbs persist in most subjects, at least up to 13 months.

We observed that a markedly lower proportion of subjects had N-IgG than S-IgG antibodies at 8 months after infection. Thereafter the concentration of N-IgG antibodies declined to a level that was not distinguishable from unspecific, cross-reactive antibodies among a large proportion of subjects 13 months after infection. SARS-CoV-2 N is produced abundantly during infection and since it is not a component in present vaccines or vaccine candidates it could potentially serve as a measure of past infection. However, our results clearly show that the sensitivity of our N-IgG based antibody assay is inversely proportional to the time after infection. In agreement with our findings, the more rapid

decay of N-IgG after SARS-CoV and SARS-CoV-2 infection has also been reported in other studies (32, 35, 36). The loss of sensitivity of SARS-CoV-2 N based antibody assays over time likely results not only from the decay of the antibodies, but from the difficulty of differentiating very low concentrations of SARS-CoV-2-specific antibodies from cross-reactive N antibodies induced by past infections with common cold human coronaviruses that share highly conserved regions (37).

Even though NAbs persist relatively long in most subjects, neutralization efficiency against the Alpha (B.1.1.7), Beta (B.1.351) and Delta (B.1.617.2) variants was decreased compared to the wild-type virus. This was emphasized in subjects who had recovered from mild disease representing the majority of COVID-19 cases (1). Indeed, mild symptomatic or asymptomatic individuals may develop no or only low levels of NAbs that may wane relatively quickly after infection (38).

In line with earlier observations 9 (13) and 12 months after infection (12), we found that NAb levels against the Alpha variant were only slightly reduced, while NAb levels against the Beta variant were considerably declined compared to the wild-type virus. The Beta variants have been shown to evade antibody responses induced upon infection as well as vaccination (21-23, 39, 40). Although the NAb levels were declined against the Beta variant, we observed that over 60% of hospitalized subjects were seropositive a year after infection, indicating long-lived cross-neutralization capacity induced by severe disease.

We detected substantially declined NAb titers against the Delta variant in subjects with mild disease, similar to what has been previously reported after vaccination or up to 12 months after SARS-CoV-2 infection (24, 25, 41-43). However, we observed that over 80% of the subjects who had recovered from severe disease were seropositive against the Delta variant. This is in line with one study reporting only modestly reduced (88%) NAb levels against the Delta variant 2-4 weeks after second vaccine dose (44). Our results support the previous findings that the emerging variant Delta partially but significantly escapes NAbs (24, 25).

One previous study reported lower seropositivity rates one year after mild SARS-CoV-2-infection compared to our results; 58% were positive for S1-IgG and 85% for S-IgG measured with enzyme immunoassay and 58% had NAb (11). Direct comparison of the IgG concentrations and NAb titers between studies may not be possible since the age groups, viruses, as well as the serological tests, differed. Neutralizing antibody tests have not been standardized and among other things, the starting dilutions of serum samples may vary between assays. The microneutralization assay used in this study utilized live virus and the starting dilution of 1:4 further enhances the sensitivity of the assay in detecting low levels of NAbs.

In our study population, we could not see a gender effect in hospitalized individuals, as previously reported (6, 31). However, hospitalized subjects ≥60 years tended to have slightly higher IgG and NAb levels compared to hospitalized subjects <60 years suggesting more severe infection in the elderly age group. Although there was no overall difference between the genders, especially males with mild disease had markedly lower NAb titers for all viruses compared to individuals who recovered from severe disease.

There is a major research effort to produce effective SARS-CoV-2 vaccines. The long-term persistence of immunity after vaccination is, however, largely unknown. Evidence from convalescent sera from individuals who have recovered from infection may help determine for how long immunity persists, and whether antibodies might protect against re-infection. Previous data shows that, when measured as IgG antibodies against S protein or RBD and NAb, immune response after two doses of SARS-CoV-2 vaccine is similar to that observed in convalescent sera from COVID-19 patients (45-48). Evidence of persistence of immunity after infection will help in predicting the persistence of immunity after SARS-CoV-2 vaccination.

We recognize certain limitations in our study. Due to high SARS-CoV-2 vaccine coverage in the older age groups (≥60 years of age) at the time of our study, only 11% of the participants were ≥60 years of age, the age group with the highest disease incidence and morbidity. Our results may not

necessarily apply to all age groups. The number of subjects selected for the NAb titer comparison was limited but the study subjects were matched by disease severity, age and gender and randomly selected from the participants.

Previous studies have indicated that the presence of antibodies to SARS-CoV-2 was associated with a significantly reduced risk of SARS-CoV-2 reinfection among healthcare workers for up to 7 months after infection (27, 49). We observed that S-IgG antibodies and NAbs persist at least a year after infection in most individuals. This strongly suggests that protection against re-infection is long-lived, although antibody-mediated immunity may not persist equally well among elderly subjects. A previous study found that patients >60 years had fewer memory B cells secreting total IgG and RBD-specific IgG than patients <60 years old 9 months after infection (9). We observed that IgG concentrations declined from 8 to 13 months more substantially in subjects ≥60 years compared to younger age groups. A similar more rapid decline in NAb concentrations was observed among the elderly compared to younger subjects who were followed up to 6 months following vaccination (50). The results of our study support previous findings indicating that protection against infection mediated by NAbs may be impaired against the VOCs, especially after a mild disease. While in the absence of NAbs reinfection is possible, cellular immunity is not similarly affected by mutations in the RBD site (22) and is likely to provide long-term protection against severe disease.

Materials and methods

Study design and participants

In October 2020, 2586 subjects ≥18 years of age, native language Finnish or Swedish, living within five selected hospital districts in Finland and with a polymerase chain reaction (PCR)-confirmed COVID-19 diagnosis between February 29th and April 30th 2020 were identified in the National Infectious Disease Register and invited to participate in the follow-up study. Subjects within

institutional care were excluded. Informed consent was obtained from all study subjects before sample collection. A total of 1292 (50%) subjects (median age 50.0, range 17.3-94.3) with PCR-confirmed COVID-19 participated and donated a blood sample for determination of SARS-CoV-2 specific serum antibodies 5.9 to 9.9 months (median 7.6 months) after infection. All those previously enrolled and still living in the same hospital district (n=1227) were invited to a follow-up visit and blood sampling a year after the COVID-19 diagnosis in March-April 2021. By May 21st 2021 altogether 995 participants (median age 52.5, range 17.6-95.6 years) had participated at 12.7 months (median, range 11.7 to 14.3 months) after the diagnosis of PCR-confirmed COVID-19. Demographics, clinical characteristics and SARS-CoV-2 vaccination history of the participants were collected from the National Infectious Disease Register, the Care Register for Health Care, the Register of Primary Health Care Visits and the National Vaccination Registry and are summarized in Table 1. The disease severity was defined as severe or mild. Severe infection was defined as an individual with laboratory-confirmed COVID-19 and who required hospital treatment. Mild infection was defined as an individual with laboratory-confirmed COVID-19 without hospital treatment. Since late December 2020 SARS-CoV-2 vaccinations have been offered according to the national recommendations in Finland.

Sample processing and selection of samples

Sera were separated by centrifugation, aliquoted and stored at -20°C or below. For assessment of NAbs, sera were heat-inactivated (56°C for 30 min) and then stored at -20°C or below.

For assessment of persistence of serum antibodies 8 months following PCR-confirmed COVID-19 diagnosis, all samples taken ≤10 months after diagnosis (n=1292) were selected for assessment of SARS-CoV-2 IgG antibody concentration and NAbs (positive/borderline/negative). For assessment of antibody persistence 13 months after infection, 400/995 sera were randomly selected for determination of SARS-CoV-2 IgG antibody concentration and NAbs. Selection criteria were: 8-month

sample available, PCR-confirmed COVID-19 diagnosis, no documentation of SARS-CoV-2 vaccination in the Register of Primary Health Care Visits by June 10th 2021. Further, samples of subjects with ≥30% increase in IgG antibody concentration to both SARS-CoV-2 S glycoprotein antigens (full-length spike protein (SFL) and RBD) between 8- and 13-month blood sampling (n=29) were excluded from the analysis. An additional four samples were excluded due to the late discovery of these samples not meeting selection criteria. Of the four samples two were excluded due to vaccination and two due to samples taken >10 months after infection. Consequently, 367 sera were selected.

For comparison of NAb titers against a wild-type virus and VOCs (Alpha, Beta and Delta), 80/536 13-month sera screened to NAb (titer ≥6 against wild-type virus) were randomly selected as mentioned above. Later observed ≥30% increase in IgG antibody concentration between 8- and 13-month samples excluded 2/80 samples leaving total sample size to 78. SARS-CoV-2 IgG antibody concentration was measured from this cohort to ensure its comparability to the other 367 sera selected.

SARS-CoV-2 MNT

A cytopathic effect based MNT was performed as previously described (51, 52). Briefly, heat-inactivated serum samples were 2-fold serially diluted starting from 1:4 in Eagle's minimum essential medium supplemented with penicillin, streptomycin and 2% of heat-inactivated fetal bovine serum. At the biosafety level 3 laboratory, pre-titrated virus was added to obtain 100 x tissue culture infectious dose 50% per well following incubation for 1 h at +37°C, 5% CO_2. African green monkey kidney epithelial (VeroE6) cells were added and the 96-well tissue culture plates were incubated at +37°C, 5% CO_2 for 4 days. Wells were fixed with 30% formaldehyde and stained with crystal violet. Results were expressed as MNT titers corresponding to the reciprocal of the serum dilution that inhibited 50% of SARS-CoV-2 infection observed by the cytopathic effect of inoculated cells. MNT titer ≥6 was considered positive, borderline when 4 and negative when <4. Borderline values were

further confirmed with biological repeats. For titer comparison, a titer of 192 was measured for the WHO International Standard (NIBSC 20/136 (53)) using the wild-type virus Fin1-20.

SARS-CoV-2 viruses selected for MNT

All samples were screened with wild-type virus Fin1-20 (B lineage): hCoV-19/Finland/1/2020 (GISAID accession ID EPI_ISL_407079; GenBank accession ID MZ934691) for NAb positivity. Fin1-20 was the first SARS-CoV-2 strain detected in Finland in January 2020. Virus isolation and propagation were performed in Vero E6 cells (51). A smaller subset of samples was analyzed also with VOCs isolated in Finland during January 2021: Fin34-21, Fin32-21 and May 2021: Fin37-21, which stand for the Alpha, Beta and Delta variant, respectively. Alpha variant (B.1.1.7) Fin34-21 indicates the isolate hCoV-19/Finland/THL-202102301/2021 (EPI_ISL_2590786; MZ944886). Spike region of the isolate hCoV-19/Finland/THL-202101018/2021 (Fin32-21) showed typical Beta variant (B.1.351) amino acid changes (EPI_ISL_3471851; MZ944846). The Delta variant (B.1.617.2) Fin37-21 indicates hCoV-19/Finland/THL-202117309/2021 (EPI_ISL_2557176; MZ945494). All variant viruses were isolated and propagated (passages 1-2) in VeroE6-TMPRSS2-H10 cells (54) and further propagated in Vero E6 cells (passage 3) for MNT.

SARS-CoV-2 fluorescent multiplex immunoassay (FMIA)

The SARS-CoV-2 FMIA has been previously described in detail by Ekström et al. (52) and Solastie et al. (55). Briefly, diluted sera, reference and controls were mixed with microspheres conjugated with SARS-CoV-2 N and SFL and RBD of the spike protein. IgG antibodies were detected by R-Phycoerythrin-conjugated secondary antibody and median fluorescence intensity was measured with MAGPIX system (Luminex) and BAU (U/ml) were interpolated from 5-parameter logistic curves with xPONENT (v. 4.2, Luminex) created by 7-point serial 4-fold diluted reference sera calibrated against WHO International Standard (NIBSC code 20/136; (53)). When the median fluorescence

intensity of a sample was below the linear range of the reference, the sample was assigned an antibody concentration half of the limit of detection (0.0094, 0.012 and 0.0057 BAU/ml for N-, SFL- and RBD-IgG). A sample was considered positive for SARS-CoV-2 S-IgG when SFL and RBD specific antibody concentrations were ≥0.089 and ≥0.13 BAU/ml, respectively. A sample was considered positive for N-IgG when N-IgG concentration was ≥0.58 BAU/ml. The cut-offs for seropositivity were determined during clinical validation of the FMIA and yielded both sensitivity and specificity of 100% for SFL- and RBD-IgG and 98.6% and 100% for N-IgG for samples taken 13 to 150 days post onset of symptoms, respectively (52, 55).

Statistical methods

We calculated the geometric mean concentrations (GMC) and GMTs with 95% confidence intervals (CI) for IgG and NAb levels, respectively. We assessed the statistical differences in antibody levels between groups using the Kruskal-Wallis test with Bonferroni correction. Differences in mean IgG concentrations between 8 and 13 months after infection were compared using Students paired t-test and log-transformed data. The statistical significance level of difference was set to $p < 0.05$. We used Spearman correlation in the correlation analyses. MNT titers <4 were assigned a titer value of 2. Samples with IgG concentrations below the limit of detection were assigned an antibody concentration equal to half of the limit of detection. Statistical analyses were performed using SPSS v27 and R (v4.0.4) with Rstudio (v1.4.1106).

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request. The complete data are not publicly available due to privacy or ethical restrictions.

References

1. Wajnberg A, Amanat F, Firpo A, Altman DR, Bailey MJ, Mansour M, McMahon M, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020 Dec 4;370(6521):1227-30. doi: 10.1126/science.abd7728. Epub 2020 Oct 28.

2. Wang C, Li W, Drabek D, Okba NMA, van Haperen R, Osterhaus ADME, van Kuppeveld FJM, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020 May 4;11(1):2251. doi: 10.1038/s41467-020-16256-y.

3. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Nature. 2020 Aug;584(7819):115-9. doi: 10.1038/s41586-020-2380-z. Epub 2020 May 26.

4. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, Subbarao K, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021 May 17. doi: 10.1038/s41591-021-01377-8. Epub 2021 May 17.

5. Figueiredo-Campos P, Blankenhaus B, Mota C, Gomes A, Serrano M, Ariotti S, Costa C, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in COVID-19 patients and healthy volunteers up to 6

months post disease onset. Eur J Immunol. 2020 Dec;50(12):2025-40. doi: 10.1002/eji.202048970. Epub 2020 Nov 10.

6. Pradenas E, Trinité B, Urrea V, Marfil S, Ávila-Nieto C, Rodríguez de la Concepción ML, Tarrés-Freixas F, et al. Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes. Med (N Y). 2021 Mar 12;2(3):313-20.e4. doi: 10.1016/j.medj.2021.01.005. Epub 2021 Jan 31.

7. Gaebler C, Wang Z, Lorenzi JCC, Muecksch F, Finkin S, Tokuyama M, Cho A, et al. Evolution of antibody immunity to SARS-CoV-2. Nature. 2021 Mar;591(7851):639-44. doi: 10.1038/s41586-021-03207-w. Epub 2021 Jan 18.

8. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, Grifoni A, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science. 2021 Feb 5;371(6529):eabf4063. doi: 10.1126/science.abf4063. Epub 2021 Jan 6.

9. Yao L, Wang GL, Shen Y, Wang ZY, Zhan BD, Duan LJ, Lu B, et al. Persistence of Antibody and Cellular Immune Responses in COVID-19 patients over Nine Months after Infection. J Infect Dis. 2021 May 12. doi: 10.1093/infdis/jiab255.

10. Grzelak L, Velay A, Madec Y, Gallais F, Staropoli I, Schmidt-Mutter C, Wendling MJ, et al. Sex differences in the evolution of neutralizing antibodies to SARS-CoV-2. J Infect Dis. 2021 Mar 7. doi: 10.1093/infdis/jiab127.

11. Choe PG, Kim KH, Kang CK, Suh HJ, Kang E, Lee SY, Kim NJ, et al. Antibody Responses One Year after Mild SARS-CoV-2 Infection. J Korean Med Sci. 2021 May 31;36(21):e157. doi: 10.3346/jkms.2021.36.e157.

12. Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, Hoffmann HH, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. Nature. 2021 Jun 14. doi: 10.1038/s41586-021-03696-9. Epub 2021 Jun 14.

13. Planas D, Bruel T, Grzelak L, Guivel-Benhassine F, Staropoli I, Porrot F, Planchais C, et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat Med. 2021 May;27(5):917-24. doi: 10.1038/s41591-021-01318-5. Epub 2021 Mar 26.

14. Patil HP, Rane PS, Shrivastava S, Palkar S, Lalwani S, Mishra AC, Arankalle VA. Antibody (IgA, IgG, and IgG Subtype) Responses to SARS-CoV-2 in Severe and Nonsevere COVID-19 Patients. Viral Immunol. 2021 Apr;34(3):201-9. doi: 10.1089/vim.2020.0321. Epub 2021 Mar 3.

15. Sterlin D, Mathian A, Miyara M, Mohr A, Anna F, Claër L, Quentric P, et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2. Sci Transl Med. 2021 Jan 20;13(577):eabd2223. doi: 10.1126/scitranslmed.abd2223. Epub 2020 Dec 7.

16. Iyer AS, Jones FK, Nodoushani A, Kelly M, Becker M, Slater D, Mills R, et al. Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020 Oct 8;5(52):eabe0367. doi: 10.1126/sciimmunol.abe0367.

17. Marot S, Malet I, Leducq V, Zafilaza K, Sterlin D, Planas D, Gothland A, et al. Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers. Nat Commun. 2021 Feb 8;12(1):844-9. doi: 10.1038/s41467-021-21111-9.

18. Seow J, Graham C, Merrick B, Acors S, Pickering S, Steel KJA, Hemmings O, et al. Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nat Microbiol. 2020 Dec;5(12):1598-607. doi: 10.1038/s41564-020-00813-8. Epub 2020 Oct 26.

19. Lauring AS, Hodcroft EB. Genetic Variants of SARS-CoV-2-What Do They Mean? JAMA. 2021 Feb 9;325(6):529-31. doi: 10.1001/jama.2020.27124.

20. Abdool Karim SS, de Oliveira T. New SARS-CoV-2 Variants - Clinical, Public Health, and Vaccine Implications. N Engl J Med. 2021 May 13;384(19):1866-8. doi: 10.1056/NEJMc2100362. Epub 2021 Mar 24.

21. Anichini G, Terrosi C, Gori Savellini G, Gandolfo C, Franchi F, Cusi MG. Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants. Vaccines (Basel). 2021 May 18;9(5):517. doi: 10.3390/vaccines9050517.

22. Geers D, Shamier MC, Bogers S, den Hartog G, Gommers L, Nieuwkoop NN, Schmitz KS, et al. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. Sci Immunol. 2021 May 25;6(59):eabj1750. doi: 10.1126/sciimmunol.abj1750.

23. Jalkanen P, Kolehmainen P, Häkkinen HK, Huttunen M, Tähtinen PA, Lundberg R, Maljanen S, et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat Commun. 2021 Jun 28;12(1):3991-4. doi: 10.1038/s41467-021-24285-4.

24. Edara VV, Pinsky BA, Suthar MS, Lai L, Davis-Gardner ME, Floyd K, Flowers MW, et al. Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. N Engl J Med. 2021 Aug 12;385(7):664-666. doi: 10.1056/NEJMc2107799. Epub 2021 Jul 7.

25. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, Planchais C, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021 Aug;596(7871):276-80. doi: 10.1038/s41586-021-03777-9. Epub 2021 Jul 8.

26. Addetia A, Crawford KHD, Dingens A, Zhu H, Roychoudhury P, Huang ML, Jerome KR, et al. Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate. J Clin Microbiol. 2020 Oct 21;58(11):e02107-20. doi: 10.1128/JCM.02107-20. Print 2020 Oct 21.

27. Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, Wellington E, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). Lancet. 2021 Apr 17;397(10283):1459-69. doi: 10.1016/S0140-6736(21)00675-9. Epub 2021 Apr 9.

28. Yu J, Tostanoski LH, Peter L, Mercado NB, McMahan K, Mahrokhian SH, Mkolola JP, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science. 2020 Aug 14;369(6505):806-11. doi: 10.1126/science.abc6284. Epub 2020 May 20.

29. McMahan K, Yu J, Mercado NB, Loos C, Tostanoski LH, Chandrashekar A, Liu J, et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature. 2021 Feb;590(7847):630-4. doi: 10.1038/s41586-020-03041-6. Epub 2020 Dec 4.

30. Regev-Yochay G, Amit S, Bergwerk M, Lipsitch M, Leshem E, Kahn R, Lustig Y, et al. Decreased infectivity following BNT162b2 vaccination: A prospective cohort study in Israel. Lancet Reg Health Eur. 2021 Aug;7:100150. doi: 10.1016/j.lanepe.2021.100150. Epub 2021 Jul 7.

31. Trinité B, Tarrés-Freixas F, Rodon J, Pradenas E, Urrea V, Marfil S, Rodríguez de la Concepción ML, et al. SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity. Sci Rep. 2021 Jan 28;11(1):2608-9. doi: 10.1038/s41598-021-81862-9.

32. Grandjean L, Saso A, Ortiz AT, Lam T, Hatcher J, Thistlethwayte R, Harris M, et al. Long-Term Persistence of Spike Antibody and Predictive Modeling of Antibody Dynamics Following Infection with SARS-CoV-2. Clin Infect Dis. 2021 Jul 4. doi: 10.1093/cid/ciab607.

33. Turner JS, Kim W, Kalaidina E, Goss CW, Rauseo AM, Schmitz AJ, Hansen L, et al. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans. Nature. 2021 Jul;595(7867):421-5. doi: 10.1038/s41586-021-03647-4. Epub 2021 May 24.

34. Breton G, Mendoza P, Hägglöf T, Oliveira TY, Schaefer-Babajew D, Gaebler C, Turroja M, et al. Persistent cellular immunity to SARS-CoV-2 infection. J Exp Med. 2021 Apr 5;218(4):e20202515. doi: 10.1084/jem.20202515.

35. Chia WN, Tan CW, Foo R, Kang AEZ, Peng Y, Sivalingam V, Tiu C, et al. Serological differentiation between COVID-19 and SARS infections. Emerg Microbes Infect. 2020 Dec;9(1):1497-505. doi: 10.1080/22221751.2020.1780951.

36. Fenwick C, Croxatto A, Coste AT, Pojer F, André C, Pellaton C, Farina A, et al. Changes in SARS-CoV-2 Spike versus Nucleoprotein Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. J Virol. 2021 Jan 13;95(3):e01828-20. doi: 10.1128/JVI.01828-20. Print 2021 Jan 13.

37. Dobaño C, Santano R, Jiménez A, Vidal M, Chi J, Rodrigo Melero N, Popovic M, et al. Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies. Transl Res. 2021 Jun;232:60-74. doi: 10.1016/j.trsl.2021.02.006. Epub 2021 Feb 12.

38. Aziz NA, Corman VM, Echterhoff AKC, Müller MA, Richter A, Schmandke A, Schmidt ML, et al. Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany. Nat Commun. 2021 Apr 9;12(1):2117-5. doi: 10.1038/s41467-021-22351-5.

39. Shen X, Tang H, Pajon R, Smith G, Glenn GM, Shi W, Korber B, Montefiori DC. Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351. N Engl J Med. 2021 Jun 17;384(24):2352-4. doi: 10.1056/NEJMc2103740. Epub 2021 Apr 7.

40. Hoffmann M, Arora P, Groß R, Seidel A, Hörnich BF, Hahn AS, Krüger N, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021 Apr 29;184(9):2384-2393.e12. doi: 10.1016/j.cell.2021.03.036. Epub 2021 Mar 20.

41. Wall EC, Wu M, Harvey R, Kelly G, Warchal S, Sawyer C, Daniels R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021 Jun 19;397(10292):2331-3. doi: 10.1016/S0140-6736(21)01290-3. Epub 2021 Jun 3.

42. Yadav PD, Sapkal GN, Ella R, Sahay RS, Nyayanit DA, Patil DY, Deshpande G, et al. Neutralization against B.1.351 and B.1.617.2 with sera of COVID-19 recovered cases and vaccinees of BBV152. bioRxiv 2021 doi: https://doi.org/10.1101/2021.06.05.447177.

43. Davis C, Logan N, Tyson G, Orton R, Harvey W, Haughney J, Perkins J, et al. Reduced neutralisation of the Delta (B.1.617.2) SARS-CoV-2 variant of concern following vaccination. medRxiv 2021 doi: https://doi.org/10.1101/2021.06.23.21259327.

44. Liu J, Liu Y, Xia H, Zou J, Weaver SC, Swanson KA, Cai H, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021 Aug;596(7871):273-5. doi: 10.1038/s41586-021-03693-y. Epub 2021 Jun 10.

45. Anderson EJ, Rouphael NG, Widge AT, Jackson LA, Roberts PC, Makhene M, Chappell JD, et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020 Dec 17;383(25):2427-38. doi: 10.1056/NEJMoa2028436. Epub 2020 Sep 29.

46. Walsh EE, Frenck RW,Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020 Dec 17;383(25):2439-50. doi: 10.1056/NEJMoa2027906. Epub 2020 Oct 14.

47. Jackson LA, Anderson EJ, Rouphael NG, Roberts PC, Makhene M, Coler RN, McCullough MP, et al. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020 Nov 12;383(20):1920-31. doi: 10.1056/NEJMoa2022483. Epub 2020 Jul 14.

48. Kremsner PG, Mann P, Kroidl A, Leroux-Roels I, Schindler C, Gabor JJ, Schunk M, et al. Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2 : A phase 1 randomized clinical trial. Wien Klin Wochenschr. 2021 Aug 10:1-11. doi: 10.1007/s00508-021-01922-y.

49. Lumley SF, Wei J, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al. The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers. Clin Infect Dis. 2021 Aug 2;73(3):e699-e709. doi: 10.1093/cid/ciab004.

50. Doria-Rose N, Suthar MS, Makowski M, O'Connell S, McDermott AB, Flach B, Ledgerwood JE, et al. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19. N Engl J Med. 2021 Jun 10;384(23):2259-61. doi: 10.1056/NEJMc2103916. Epub 2021 Apr 6.

51. Haveri A, Smura T, Kuivanen S, Osterlund P, Hepojoki J, Ikonen N, Pitkäpaasi M, et al. Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020. Euro Surveill. 2020 Mar;25(11):2000266. doi: 10.2807/1560-7917.ES.2020.25.11.2000266.

52. Ekström N, Virta C, Haveri A, Dub T, Hagberg L, Solastie A, Österlund P, et al. Analytical and clinical evaluation of antibody tests for SARS-CoV-2 serosurveillance studies used in Finland in 2020. medRxiv 2021 doi: https://doi.org/10.1101/2021.01.21.21250207.

53. Mattiuzzo G, Bentley EM, Hassall M, Routley S, Richardson S, Bernasconi V, Kristiansen P, et al. Establishment of the WHO International Standard and Reference Panel for anti-SARS-CoV-2 antibody. WHO Expert Committee on Biological Standardization. WHO/BS/2020.2403; 2020.

54. Rusanen J, Kareinen L, Szirovicza L, Uğurlu H, Levanov L, Jääskeläinen A, Ahava M, et al. A

Generic, Scalable, and Rapid Time-Resolved Förster Resonance Energy Transfer-Based Assay for

Antigen Detection-SARS-CoV-2 as a Proof of Concept. mBio. 2021 May 18;12(3):e00902-21. doi:

10.1128/mBio.00902-21.

55. Solastie A, Virta C, Haveri A, Ekström N, Kantele A, Miettinen S, Lempainen J, et al. A highly

sensitive and specific SARS-CoV-2 spike- and nucleoprotein-based fluorescent multiplex

immunoassay (FMIA) to measure IgG, IgA and IgM class antibodies. medRxiv 2021 doi:

https://doi.org/10.1101/2021.07.28.21260990.

Graphical abstract

A year after wild-type SARS-CoV-2 infection high seropositivity rate was observed: 89% of subjects
had persisting neutralizing antibodies and up to 97% had anti-spike IgG antibodies. Compared to the
wild-type virus, neutralizing antibody titers were reduced for variants of concern Alpha, Beta and
Delta.

Figure 1. The study flow chart showing the selection of serum samples of the study participants for

the determination of antibody concentration and neutralizing antibodies 8 and 13 months after

infection.

Figure 2. Nucleoprotein (N), and spike protein (SFL, RBD) specific IgG concentrations (BAU/ml) with

geometric mean concentrations (95% CI) at 8 and 13 months after infection, n=367 subjects. FMIA

specific cut-off for seropositivity is indicated by a dashed red line. Each sample was tested as

technical duplicates in each experiment and the experimental precision was confirmed by two

control samples in each independent experiment.

Figure 3. Distribution and the geometric mean of IgG concentrations (BAU/ml and 95% CIs) for

nucleoprotein (N specific IgG), and spike protein (SFL and RBD specific IgG) in subjects 8 and 13

months after severe (n=47 subjects) or mild (n=320 subjects) infection. FMIA specific cut-off for

seropositivity is indicated by a dashed red line. Each sample was tested as technical duplicates in

each experiment and the experimental precision was confirmed by two control samples in each

independent experiment.

Figure 4. The proportion of subjects positive, low positive (borderline) and negative for neutralizing antibodies 13 months after infection against four SARS-CoV-2 virus strains (n=78 subjects): The wild-type virus (B), the Alpha variant (B.1.1.7), the Beta variant (B.1.351) and the Delta variant (B.1.617.2). Each sample was tested as technical duplicates in each experiment and the experimental precision was confirmed by two control samples in each independent experiment.

Figure 5. Spearman correlation (ρ) and significance (*p*) between S-IgG antibody concentrations and neutralizing antibody (NAb) titers against the wild-type virus (B) and the variants of concern: Alpha (B.1.1.7), Beta (B.1.351) and Delta (B.1.617.2). One point may represent multiple samples (n=78 subjects). Each sample was tested as technical duplicates in each experiment and the experimental precision was confirmed by two control samples in each independent experiment.